Market Access Is it time to rethink electronic prescribing in the US? It is a fact of life that most – if not all – patients will require some form of prescription medication during their lifetime.
News Ipsen licenses Simcere ADC in $1bn-plus deal Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.